Gregory L. Weaver's most recent trade in Altimmune Inc was a trade of 10,000 Common Stock, par value $0.0001 done at an average price of $3.1 . Disclosure was reported to the exchange on April 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.15 per share. | 01 Apr 2026 | 10,000 | 38,078 (0%) | 0% | 3.1 | 31,499 | Common Stock, par value $0.0001 |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.54 per share. | 06 Mar 2026 | 5,000 | 28,078 (0%) | 0% | 3.5 | 17,700 | Common Stock, par value $0.0001 |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2025 | 18,750 | 56,250 | - | - | Restricted Stock Units | |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2025 | 18,750 | 28,750 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.28 per share. | 11 Nov 2025 | 5,672 | 23,078 (0%) | 0% | 4.3 | 24,276 | Common Stock, par value $0.0001 |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 166,800 | 166,800 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 57,900 | 57,900 | - | - | Restricted Stock Units | |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.20 per share. | 13 Mar 2025 | 10,000 | 10,000 (0%) | 0% | 5.2 | 51,996 | Common Stock, par value $0.0001 |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director, EVP & CFO | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 20 Jun 2023 | 50,000 | 50,055 (0%) | 0% | 1.0 | 48,500 | Common Stock |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director, EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 2,600,000 | 2,600,000 | - | - | Stock Option (right to buy) | |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| ATAI Life Sciences N.V. | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 228,000 | 228,000 | - | - | Stock Option |